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Abstract
Background: Infections during pregnancy have the potential to adversely impact birth outcomes. We evaluated the
association between receipt of inactivated influenza vaccine during pregnancy and prematurity and small for gestational
age (SGA) births.
Methods and Findings: We conducted a cohort analysis of surveillance data from the Georgia (United States) Pregnancy
Risk Assessment Monitoring System. Among 4,326 live births between 1 June 2004 and 30 September 2006, maternal
influenza vaccine information was available for 4,168 (96.3%). The primary intervention evaluated in this study was receipt
of influenza vaccine during any trimester of pregnancy. The main outcome measures were prematurity (gestational age at
birth ,37 wk) and SGA (birth weight ,10th percentile for gestational age). Infants who were born during the putative
influenza season (1 October–31 May) and whose mothers were vaccinated against influenza during pregnancy were less
likely to be premature compared to infants of unvaccinated mothers born in the same period (adjusted odds ratio
[OR]=0.60; 95% CI, 0.38–0.94). The magnitude of association between maternal influenza vaccine receipt and reduced
likelihood of prematurity increased during the period of at least local influenza activity (adjusted OR=0.44; 95% CI, 0.26–
0.73) and was greatest during the widespread influenza activity period (adjusted OR=0.28; 95% CI, 0.11–0.74). Compared
with newborns of unvaccinated women, newborns of vaccinated mothers had 69% lower odds of being SGA (adjusted
OR=0.31; 95% CI, 0.13–0.75) during the period of widespread influenza activity. The adjusted and unadjusted ORs were not
significant for the pre-influenza activity period.
Conclusions: This study demonstrates an association between immunization with the inactivated influenza vaccine during
pregnancy and reduced likelihood of prematurity during local, regional, and widespread influenza activity periods. However,
no associations were found for the pre-influenza activity period. Moreover, during the period of widespread influenza
activity there was an association between maternal receipt of influenza vaccine and reduced likelihood of SGA birth.
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Infections during pregnancy have the potential to adversely
impact birth outcomes and fetal growth and development.
Respiratory infections—particularly those resulting in pneumo-
nia—have been associated with low birth weight and increased
risk of preterm birth [1,2]. Influenza virus is an important
respiratory pathogen that causes substantial burden of disease—
including morbidity and mortality among pregnant women, with
greater risk of influenza-related morbidity among pregnant
women than among non-pregnant and postpartum women [3].
Vaccination against influenza is the most effective tool to
prevent morbidity and mortality due to influenza. Influenza
vaccination during pregnancy provides protection for the infant as
well as the mother. A randomized controlled clinical trial in
Bangladesh demonstrated that vaccination of pregnant women
with the inactivated influenza vaccine had 63% effectiveness in
reducing laboratory-confirmed influenza in their infants [4]. Since
there is evidence of adverse fetal/newborn outcomes after
infection during pregnancy [5,6], including influenza infection
[2], it is plausible that influenza vaccination in pregnancy could
mitigate adverse birth outcomes such as prematurity and small for
gestational age (SGA) births. The potential impact of maternal
influenza immunization on birth outcomes could have important
public health implications for developed as well as developing
countries and may be of particular interest during influenza
pandemics.
The objective of this study was to evaluate whether there is an
association between receipt of inactivated influenza vaccine during
pregnancy and birth outcomes using a multiyear, population-
based, state-wide dataset from the state of Georgia (in the United
States).
Methods
We conducted a retrospective cohort analysis of a large
surveillance dataset. The primary exposure variable was receipt
of inactivated influenza vaccine during any trimester of pregnancy
by mothers of infants born between 1 June 2004 and 30
September 2006. The study period encompassed the 2004–2005
and the 2005–2006 influenza seasons (the two most recent seasons
for which the data were available at the time of analysis). The
main outcomes assessed were prematurity and SGA.
Data Sources and Study Population
We analyzed pregnancy- and birth-related data from the
Georgia Pregnancy Risk Assessment Monitoring System (PRAMS)
and influenza activity information compiled by Georgia for the
Council of State and Territorial Epidemiologists (CSTE) reports.
PRAMS is a multistate surveillance system managed by the US
Centers for Disease Control and Prevention and state health
departments, including the Georgia Department of Community
Health [7,8]. The PRAMS sample is drawn monthly from the
state’s birth file and includes resident women who have
experienced a live birth. Georgia PRAMS oversamples women
based on race (black) and birth weight (,2,500 g). We adjusted for
the oversampling by using analysis weights described elsewhere in
the methods section. PRAMS data are collected primarily by
mailed questionnaires, with telephone follow-up among non-
responders.
The Georgia PRAMS dataset contains information on maternal
influenza vaccination (during any trimester); maternal attitudes,
behaviors, and experiences before, during, and shortly after
pregnancy; and newborn birth certificate data, including birth
date and birth weight. Prematurity was defined as clinical estimate
of gestational age (at birth) as less than 37 wk. Newborns with
birth weight below the10
th percentile for their gestational age were
considered to be SGA. We used gender-specific reference values
for the US published by Oken at al. [9] to assign SGA (yes/no)
categories.
Definitions of Influenza Activity Periods
In order to model the impact of the intensity of influenza
activity in Georgia on the association between maternal influenza
vaccination and birth outcomes, we used a modified version of the
CSTE report categories of influenza activity. CSTE reports assess
the spread of influenza within each state for each week based on
lab-confirmed and syndromic data [10]. The influenza activity is
considered local if there are influenza outbreaks or an increase in
cases of influenza-like illness in a single region of the state along
with recent identification of laboratory-confirmed influenza from
that region. In the case of influenza outbreaks or increases in
influenza-like illness with recent laboratory-confirmed influenza in
at least two but fewer than half the regions of the state, the
influenza activity level is considered to be regional. If the influenza
outbreaks or increased numbers of influenza-like illness cases (plus
laboratory-confirmed cases) are reported in at least half of the
regions of the state, the influenza activity is considered to be
widespread (Figure 1). We defined the pre-influenza period as the
period between the start of the putative influenza season (October
1) and the beginning of local influenza activity (per CSTE reports).
The pre-influenza period is characterized by the availability of the
vaccine and the absence of influenza activity (Figure 1). The
definition for the pre-influenza period was similar to the one used
by other authors [11,12].
Stratified analysis was performed for the overall study period,
the putative influenza season (1 October–31 May), the pre-
influenza period (during the putative influenza season), the period
of at least local activity, the period of regional activity, and the
period of widespread activity (Figure 1).
Statistical Analysis and Confounder Assessment
In Georgia PRAMS, live births to black women and those that
are low birth weight are oversampled in order to provide enough
statistical power for stratified analyses for groups of interest
relevant to PRAMS objectives. For combined analyses, in
accordance with standard practice, analysis weights developed
by the Centers for Disease Control and Prevention [13] were used
to adjust for the sample design (e.g., to account for oversampling of
the two risk groups) and differential response rate across groups.
We used logistic regression to evaluate the association of
maternal influenza vaccine and (a) prematurity and (b) SGA.
Linear regression was used to evaluate the statistical significance of
differences between infants born to vaccinated and unvaccinated
women in terms of mean gestational age at first antenatal visit and
mean birth weight.
Confounding due to differences between the vaccinated and
unvaccinated individuals is a recognized issue in observational
studies of influenza vaccination—particularly studies evaluating
vaccine effectiveness for reducing all-cause mortality in the elderly
[12]. One approach to account for confounding is to choose a
period when the vaccine was available but the influenza virus was
not circulating as the ‘‘control’’ pre-influenza period [11,12]. In
the pre-influenza period, there should be no vaccine effect, and
observed effects during this period are assumed to be due to
confounding. Therefore, as our primary strategy for confounder
adjustment, we identified a group of covariates that would move
the odds ratios (ORs) of association between maternal influenza
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to 1.0 (i.e., no effect), hence arriving at a set of covariates that
could effectively control for confounding due to the differences
between the vaccinated and the unvaccinated women in analyses
of all influenza activity periods. We selected covariates for the
separate multivariate models for each of the birth outcomes (i.e.,
prematurity and SGA) using a modified version of the approach
described by Jackson et al. [11] and Nelson et al. [12]. Briefly,
variables for each birth outcome were evaluated for potential
confounding by selecting the covariates that, in bivariate models,
modified the association between maternal influenza vaccine and
the birth outcome and moved the OR towards 1. From this initial
group of variables, we arrived at a parsimonious model by
sequentially dropping each covariate and observing a change in
OR of the association between maternal immunization and the
birth outcome. We excluded the variable whose removal moved
the OR the most towards 1. If dropping a covariate resulted in
moving ORs away from 1 and a change in magnitude of less than
1%, we removed the covariate that caused the least change and
then repeated the process. If the change was more than 1%, we
considered the current set of covariates as the smallest group of
variables required to account for confounding.
In order to address the possibility that the confounders in the pre-
influenza period were different from the confounding factors in the
influenza activity period, we also developed secondary multivariate
models using a traditional analytic approach for confounder
adjustment. In these secondary models, the covariate list (for both
the pre-influenza-period-based and traditional adjustment) was
based on evidence in the literature regarding associations with birth
outcomes and availability of data in the Georgia PRAMS dataset.
The covariate list included the following: gestational age at first
antenatal visit, maternal age less than 19 y, maternal age more than
35 y, multiple births, maternal medical risk factors, labor/delivery
complications, birth defects, maternal diabetes (gestational and/or
non-gestational), hypertension (treated or untreated), mother
insured, multivitamin use in pregnancy, history of smoking during
pregnancy, history of alcohol use during pregnancy, black race,
education less than 12
th grade, mother’s marital status, and
maternal weight before pregnancy. The ORs for association
between the different covariates and receipt of influenza vaccine
were computed using logistic regression.
We also computed the population prevented fraction of
prematurity for the various periods of influenza activity using
the formula:
^ p pc(1{OR)
^ p pc(1{OR)zOR
where ^ p pc is the proportion of cases
vaccinated and OR is the odds ratio approximating relative risk
(we verified this assumption for our data). The formula, based on
the approach described by Kleinbaum et al. [14], is suitable for
computing the population prevented fraction when adjusted
measures of association are used. The population prevented
fraction for a vaccine estimates the reduction in an outcome given
the efficacy/effectiveness of the vaccine and the specific vaccine
coverage.
We used Stata version 10 (Stata Corporation) for statistical
analysis. Identified associations were evaluated for statistical
significance at a=0.05 using two-tailed tests, and Taylor series
linearization methods [15] were used to estimate variance.
Ethical Assessment and Institutional Review Boards
The study was reviewed and approved by the Emory University
Institutional Review Board and the Georgia Department of
Human Resources Institutional Review Board.
Results
A total of 4,326 women (and their newborns) were included in
Georgia PRAMS during the 28-mo study period. Influenza
vaccine information was available for 4,168 (96.3%) women in
PRAMS (study population); of these, 578 women (14.9%
[weighted]) had received the influenza vaccine during pregnancy.
The vaccine coverage was 19.2% (weighted) among mothers of
infants born during the putative influenza season. Out of the
122 wk of the study, at least local influenza activity was detected
during 27 wk (22.1%)—including widespread activity in 8 wk
(Figure 1). There were 1,547 premature newborns (10.6%
[weighted]) and 1,186 newborns with SGA (11.2% [weighted])
in our study population.
The odds of having received influenza vaccine during
pregnancy were lower (a) for black women than for all other
ethnic groups (OR=0.78; 95% CI, 0.62–0.98), (b) for women with
diabetes (OR=0.30, 95% CI, 0.10–0.95), and (c) for mothers who
used multivitamins in pregnancy (OR=0.64; 95% CI, 0.50–0.83)
(Table 1). Insured women were more likely to have received the
influenza vaccine (OR=1.41; 95% CI, 1.09–1.81). Likelihood of
having received an influenza vaccine during pregnancy was not
associated with any of the other binary covariates (Table 1).
Similarly, gestational age at first prenatal visit was similar for
vaccinated women and unvaccinated women (mean: 5.2 wk versus
5.3 wk; p=0.23), and maternal weight before pregnancy was
similar for vaccine recipients and non-recipients (mean: 68.3 kg
versus 68.1 kg; p=0.88).
Based on the approach of identifying covariates that produce
adjusted ORs of 1 during the pre-influenza period, the group of
covariates in the prematurity multivariate models included
gestational age for first antenatal visit, maternal diabetes
(gestational and/or non-gestational), multivitamin use in pregnan-
cy, history of alcohol use during pregnancy, education less than
12th grade, and mother married. The covariates in the primary
multivariate models for SGA included maternal age less than 19 y,
maternal medical risk factors, labor/delivery complications,
Figure 1. Influenza activity/analysis periods. The numbers indicate births in each of the analysis periods.
doi:10.1371/journal.pmed.1000441.g001
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alcohol use during pregnancy.
In unadjusted models, and in models with covariates based on
lack of effects in the pre-influenza season, infants born during the
putative influenza season (1 October–31 May) and whose mothers
were vaccinated against influenza during pregnancy were less likely
to be premature than infants of unvaccinated mothers born in the
same period (adjusted OR=0.60; 95% CI, 0.38–0.94). The
magnitude of effect of maternal influenza vaccine on prematurity
increased during the period when there was at least local influenza
activity in any part of the state (adjusted OR=0.44; 95% CI, 0.26–
0.73) and was the highest for those born during the period of
widespread influenza activity (adjusted OR=0.28; 95% CI, 0.11–
0.74) (Table 2). The adjusted and unadjusted ORs were not
significant for the association between receipt of maternal influenza
vaccine and prematurity for the pre-influenza activity period or for
the analysis without consideration of influenza activity (Table 2).
Compared with newborns of unvaccinated women, those born
to vaccinated mothers had lower odds of SGA (adjusted
OR=0.31; 95% CI, 0.13–0.75) during the period of widespread
influenza activity (Table 3). Although the magnitude of the ORs of
the association between maternal influenza vaccine and SGA
generally increased with the increase in the intensity of influenza
activity, these associations were not statistically significant (other
than for the period of widespread activity) (Table 3). The
associations observed in the secondary multivariate models using
the traditional approach were qualitatively similar to the
associations in the primary multivariate models (Tables 2 and 3).
Newborns of vaccinated women were, on average, 96.7 g
heavier than newborns of unvaccinated women (3,348 g versus
3,251 g; p=0.002). During the putative influenza season, the
difference between the two groups increased to 113 g (3,360 g for
the vaccinated group versus 3,247 g for the unvaccinated group;
p=0.004). There were no significant differences in birth weights
outside the putative influenza season (3,317 g [vaccinated] versus
3,255 g [unvaccinated]; p=0.233).
There was no statistical interaction by specific influenza season
(i.e., 2004–2005 and 2005–2006) for all analyses of prematurity,
SGA, and birth weight (for all interaction terms: p.0.05—detailed
data available on request). Moreover, the association between
maternal influenza vaccine and birth outcomes was qualitatively
similar for the two influenza seasons. For example, during the
period of widespread influenza activity, the adjusted ORs for
prematurity were 0.17 (95% CI, 0.03–0.86) for the 2004–2005
season and 0.32 (95% CI, 0.10–1.14) for the 2005–2006 season.
The fraction of prematurity prevented in the population during
the study period (population prevented fraction of prematurity)
was 0% for the pre-influenza activity period and 7.9% for the
putative influenza season. The population prevented fraction
increased during the periods of influenza activity (at least local
activity, 15.7%; at least regional activity, 17.5%; widespread
activity, 17.5%).
Table 1. Receipt of influenza vaccine during pregnancy categorized by maternal characteristics.
Characteristic
Maternal/Demographic Category:
Yes
Maternal/Demographic Category:
No p-Value OR (95% CI)
a
Vaccinated
b [n
(%)] Total
c [n (%)]
Vaccinated
b [n
(%)] Total
c [n (%)]
Maternal age less than 19 y 92 (18.3) 536 (11.5) 486 (14.5) 3,632 (88.5) 0.13 1.32 (0.92–1.89)
Maternal age more than 35 y 79 (17.7) 521 (12.5) 499 (14.6) 3,647 (87.5) 0.2 1.26 (0.89–1.79)
Multiple births (during current gestation) 184 (9.0) 282 (1.9) 393 (15.1) 3,876 (98.1) 0.11 0.56 (0.27–1.16)
Maternal medical risk factors
d 184 (13.8) 1,486 (29.6) 393 (15.5) 2,689 (70.4) 0.34 0.88 (0.66–1.15)
Labor/delivery complications
e 248 (16.3) 1,735 (32.4) 330 (14.3) 2,433 (67.6) 0.23 1.17 (0.91–1.51)
Birth defect 16 (15.4) 87 (1.4) 562 (15.0) 4,081 (98.6) 0.94 1.03 (0.41–2.61)
Maternal diabetes 10 (5.2) 100 (2.0) 567 (15.2) 4,057 (98.0) 0.03 0.30 (0.08–0.95)
Hypertension 39 (15.1) 316 (4.1) 538 (15.0) 3,841 (95.9) 0.97 1.01 (0.57–1.78)
Mother insured 325 (17.1) 2,099 (52.1) 253 (12.7) 2,060 (47.9) 0.0007 1.41 (1.09–1.81)
Multivitamin use in pregnancy 324 (12.7) 2,587 (60.1) 252 (18.4) 1,565 (39.4) 0.0005 0.64 (0.50–0.83)
History of smoking during pregnancy 31 (9.3) 306 (6.9) 545 (15.4) 3,847 (93.1) 0.06 0.56 (0.31–1.02)
History of alcohol use during pregnancy 7 (31.9) 33 (0.7) 569 (14.8) 4,120 (99.30) 0.08 2.7 (0.86–8.43)
Black race 282 (12.9) 2,117 (31.9) 294 (15.9) 2,035 (68.1) 0.03 0.78 (0.62–0.98)
Education less than 12th grade 95 (16.1) 610 (17.3) 420 (13.7) 3,226 (82.7) 0.28 1.21 (0.85–1.71)
Mother married 307 (15.6) 2,219 (58.5) 271 (14.1) 1,945 (41.5) 0.36 1.22 (0.87–1.44)
All percentages calculated with analytical weights.
aRatio of the odds of having received influenza vaccine by mothers in each binary (yes/no) category of a covariate, e.g., the odds of having received an influenza vaccine
were 22% higher among married women than among unmarried women.
bNumber and proportion of mothers in each of the binary (yes/no) category of a covariate who received the influenza vaccine, e.g., 14.1% of unmarried mothers had
received the influenza vaccine compared to 15.6% of married women.
cTotal (and weighted percent) of respondants with ‘‘Yes’’ or ‘‘No’’ in a maternal/demographic characteristic category (out of all respondents).
dMedical risk factors include acute or chronic lung disease; anemia (hemoglobin ,10 gm/dl or hematocrit ,30%); cardiac disease; diabetes; eclampsia; genital herpes;
hemoglobinopathy; hydramnios/oligohydramnios; chronic hypertension; pregnancy-induced hypertension, incompetent cervix; previous infant .4,000 g; previous
preterm, SGA, or low birth weight delivery; renal disease; Rh sensitization; rubella; syphilis; and uterine bleeding.
eLabor/delivery complications include abruptio placenta, anesthetic complications, breech presentation, cephalopelvic disproportion, cord prolapse, dysfunctional
labor, excessive bleeding, febrile (100uF/38uC), fetal distress, moderate to heavy meconium staining, placenta previa, labor ,3 h, premature rupture of membranes
.12 h, labor .20 h, and seizures during labor.
doi:10.1371/journal.pmed.1000441.t001
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This study demonstrates an association between immunization
with the inactivated influenza vaccine during pregnancy and
reduced likelihood of prematurity during local, regional, and
widespread influenza activity periods. For births during the 8 wk
of widespread influenza activity, the odds of prematurity were
approximately 70% lower among the newborns of the vaccinated
mothers compared to mothers who did not receive the influenza
vaccine. During the period of widespread influenza activity there
was also an association between maternal receipt of influenza
vaccine and reduced likelihood of SGA. The magnitude of
association between influenza vaccine and prematurity (as
measured by the values of ORs) increased with the increase in
the intensity of influenza activity and was higher for the 2004–
2005 season than for the 2005–2006 season. Based on laboratory
and epidemiologic criteria, the 2004–2005 influenza season was
more intense than the 2005–2006 season in the US [16]. Although
the SGA-related ORs were not statistically significant for influenza
activity periods except for the period of widespread activity, the
overall ‘‘gradient’’ of effect in the point estimates of the ORs was
qualitatively similar to that of prematurity. The increase in the
impact of maternal influenza vaccines on birth outcomes by
influenza activity, both in terms of ORs and population prevented
fractions, supports the validity of our findings.
The possibility of confounding due to differences between
vaccinated and unvaccinated individuals included in observational
studies of influenza immunization is well recognized [12]. The most
significant type of confounding in influenza studies is due to a higher
likelihood of individuals with high functional capacity (i.e., healthier
Table 2. ORs of prematurity by maternal influenza vaccine status (ORs,1 imply a protective association of the vaccine).
Analysis Period Unadjusted Models Primary Adjusted Models
a Secondary Adjusted Models
b
OR (95% CI)
c p-Value OR (95% CI)
c p-Value OR (95% CI)
c p-Value
All seasons/periods 0.75 (0.54–1.04) 0.09 0.82 (0.57–1.18) 0.28 0.83 (0.55–1.26) 0.38
Putative influenza season (Oct–May) 0.60 (0.41–0.89) 0.01 0.60 (0.38–0.94) 0.02 0.54 (0.32–0.90) 0.02
Pre-influenza activity period 0.74 (0.34–1.59) 0.44 1.00 (0.39–2.54) 1.00 0.81 (0.30–2.16) 0.67
Period of at least local influenza activity 0.56 (0.33–0.96) 0.04 0.44 (0.26–0.73) 0.001 0.40 (0.24–0.68) 0.001
Period of at least regional influenza activity 0.57 (0.30–1.10) 0.10 0.41 (0.23–0.73) 0.003 0.36 (0.19–0.68) 0.002
Period of widespread influenza activity 0.34 (0.16–0.73) 0.006 0.28 (0.11–0.74) 0.01 0.27 (0.08–0.86) 0.03
aThe primary adjusted models were based on the approach of identifying covariates that produce adjusted ORs of 1 during the pre-influenza period and included the
following covariates: gestational age for first antenatal visit, maternal diabetes (gestational and/or non-gestational), multivitamin use in pregnancy, history of alcohol
use during pregnancy, education less than 12th grade, and mother married.
bIn the secondary adjusted models, the covariates included gestational age at first antenatal visit, maternal age less than 19 y, maternal age more than 35 y, multiple
births, maternal medical risk factors, labor/delivery complications, birth defects, maternal diabetes (gestational and/or non-gestational), hypertension (treated or
untreated), mother insured, multivitamin use in pregnancy, history of smoking during pregnancy, history of alcohol use during pregnancy, black race, education less
than 12th grade, mother’s marital status, and maternal weight before pregnancy. The ORs for association between the different covariates and receipt of influenza
vaccine were computed using logistic regression.
cRatio of the odds of prematurity in newborns of mothers who received influenza vaccine during pregnancy compared to mothers who did not receive the vaccine by
intensity of influenza activity, e.g., in the analysis of all seasons/periods, the (unadjusted) odds of prematurity were 25% lower among the infants of mothers who
received the influenza vaccine during pregnancy than among infants whose mothers who did not receive the vaccine.
doi:10.1371/journal.pmed.1000441.t002
Table 3. ORs of being SGA by maternal influenza vaccine status (ORs,1 imply a protective association of the vaccine).
Analysis Period Unadjusted Models Primary Adjusted Models
a Secondary Adjusted Models
b
OR (95% CI)
c p-Value OR (95% CI)
c p-Value OR (95% CI)
c p-Value
All seasons/periods 0.84 (0.60–1.19) 0.33 0.83 (0.59–1.17) 0.29 0.96 (0.66–1.42) 0.86
Putative influenza season (Oct–May) 0.74 (0.47–1.15) 0.18 0.74 (0.47–1.15) 0.18 0.84 (0.50–1.40) 0.50
Pre-influenza activity period 1.07 (0.47–2.42) 0.87 1.02 (0.45–2.29) 0.96 1.02 (0.42–2.48) 0.96
Period of at least local influenza activity 0.73 (0.40–1.33) 0.30 0.74 (0.39–1.39) 0.35 0.68 (0.32–1.46) 0.33
Period of at least regional influenza activity 0.80 (0.39–1.64) 0.54 0.76 (0.34–1.71) 0.51 0.70 (0.27–1.87) 0.49
Period of widespread influenza activity 0.32 (0.14–0.73) 0.007 0.31 (0.13–0.75) 0.009 0.29 ( 0.09–0.91) 0.04
aThe primary adjusted models were based on the approach of identifying covariates that produce adjusted ORs of 1 during the pre-influenza period and included the
following covariates: gestational age for first antenatal visit, maternal diabetes (gestational and/or non-gestational), multivitamin use in pregnancy, history of alcohol
use during pregnancy, education less than 12th grade, and mother married.
bIn the secondary adjusted models, the covariates included gestational age at first antenatal visit, maternal age less than 19 y, maternal age more than 35 y, multiple
births, maternal medical risk factors, labor/delivery complications, birth defects, maternal diabetes (gestational and/or non-gestational), hypertension (treated or
untreated), mother insured, multivitamin use in pregnancy, history of smoking during pregnancy, history of alcohol use during pregnancy, black race, education less
than 12th grade, mother’s marital status, and maternal weight before pregnancy. The ORs for association between the different covariates and receipt of influenza
vaccine were computed using logistic regression.
cRatio of the odds of being SGA among newborns of mothers who received influenza vaccine during pregnancy compared to those born to mothers who did not
receive the vaccine by intensity of influenza activity, e.g., in the analysis of all seasons/periods, the (unadjusted) odds of being SGA were 84% lower among the
newborns of mothers who received influenza vaccine during pregnancy than among infants whose mothers who did not receive the vaccine.
doi:10.1371/journal.pmed.1000441.t003
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‘‘healthy user effect.’’ However, most observational studies where
significant confounding has been documented were conducted in the
elderly and included a relatively nonspecific end point of all-cause
mortality. It is reasonable to assume that, compared to older
individuals, women of reproductive age may be less likely to have
significant functional limitation even in the presence of co-morbidities.
Therefore, influenza vaccine studies in this age group may be less
likely to suffer from bias due to the healthy user effect. Moreover, we
found no statistically significant difference between the vaccinated
women and the unvaccinated women in terms of gestational age at
which they sought antenatal care. On the other hand, the possibility of
other confounders cannot be discounted in studies involving pregnant
women. In order to address confounding, we used the pre-influenza
period (i.e., the season where vaccine was available but there was
minimal circulation of influenza virus) as the ‘‘control’’ period. The
use of the pre-influenza period for selecting confounders from a broad
set of covariates is an approach suggested by Nelson et al. [12] and
Jackson et al. [11] that takes advantage of the seasonality of influenza
circulation. The associations observed in our study were robust to
adjustment for confounders identified using this approach (and the
more traditional approach)—supporting the validity of our findings.
Influenza virus, particularly seasonal influenza virus, rarely
crosses the placenta [3,17,18]. However, the effect of infection on
prematurity is thought be at least partially mediated through
inflammatory pathways [5,6]. Increase in pro-inflammatory
cytokines (e.g., IL-1, IL-6 and TNF-a) and reduction in anti-
inflammatory cytokines (e.g., IL-10) have been linked to preterm
labor [6,19,20]. IL-1 stimulates the amnion and the decidua to
produce prostaglandins and can stimulate myometrial contractions
[20]. Prostaglandins are known to play an important role in the
initiation and progression of labor [21]. Moreover, in animal
models, administration of IL-1 results in preterm birth [20].
Similarly, TNF-a induces the amnion, the decidua, and the
myometrium to produce prostaglandins, and administration of
TNF-a to pregnant animals can induce preterm labor [19,22].
Recent studies have shown that influenza virus infection induces
gene expression of pro-inflammatory cytokines including IL-1b,
IL-6, TNF-a, interferon (IFN)-b, IFN-a, and granulocyte
macrophage colony-stimulating factor (GM-CSF) [19].
In addition to biological plausibility, there is epidemiological
evidence of an association between maternal infection and preterm
birth [5]. The association is strongest for intrauterine viral infections
and systemic and intrauterine bacterial infections [5,6]. Viral
infection outside the reproductive tract, including influenza
infection, may also play a role in the etiology of prematurity. For
example, in an analysis of 1957–1958 data, newborns of women
who had serological evidence of ‘‘Asian’’ (pandemic) influenza
during pregnancy were 50% more likely to be premature compared
to newborns of uninfected women [2]. Moreover, a recent literature
review found that SARS infection in the second or third trimester of
pregnancy may be associated with spontaneous preterm delivery
and early cesarean sections for deteriorating medical condition,
although only 16 such cases were identified in the literature [23].
Moreover, in studies in China and Hungary, birth defects were
associated with history of influenza [24,25].
However, a few observational studies have failed to demonstrate
an association between influenza infection and birth outcomes
[26,27]. The lack of observed effect in some studies could be due
to a true lack of association, small or difficult to measure effect size,
challenges related to the study population (e.g., administrative
datasets), or non-differential misclassification due to challenges in
retrospectively identifying influenza infection. Although less than
ideal, modeling receipt of influenza vaccine as the exposure/
independent variable reduces the likelihood and the intensity of
non-differential misclassification bias.
Preterm births represent a significant burden to health care and
society [5]. Like several developed countries, there has been an
increase in the rate of preterm births in the US, which rose from
9.5% in 1981 to 12.8% in 2006 [28,29]. Although the etiology of
prematurity is complex [5] and not completely understood, our
results suggest that at least a fraction of preterm births may be
preventable through maternal influenza vaccination.
The association between maternal influenza vaccination and
SGA was only statistically significant (and the highest in magnitude)
for the period of widespread influenza activity. Possible reasons for
the effect being limited to the period of highest influenza activity
include the following: (a) in a developed country setting, the effect of
maternal influenza infection on fetal growth is milder than the effect
on prematurity; (b) SGA represents fetal compromise resulting from
infection that is insufficient to trigger early parturition, but may
result in the delayed observation of growth restriction (i.e., the
observation inthe widespread activityperiodmaybe the cumulative
effect of previous periods). Moreover, in the vaccinated group, the
birth weight distribution in the pre-influenza period was different
from the distribution in the period of widespread activity (see Text
S1). However, the difference in mean birth weights (in the
vaccinated group) between these two periods was not statistically
significant (p=0.74). Since the ostensible increase in birth weight in
thewidespread activity periodcompared tothe pre-influenza period
in the vaccinated group cannot easily be explained by vaccine
action, this difference—although non-significant—may suggest
confounding vis-a `-vis the birth weight outcome.
This study has a few limitations and strengths. Although we
assessed and adjusted for many covariates, like any observational
study, there is a possibility of residual confounding and selection
bias. Moreover, data on influenza infection during pregnancy were
not included in the PRAMS dataset. Although the primary
explanation of the effects of influenza immunization in pregnancy
on birth outcomes is through prevention of infection, having
influenza infection data would have provided additional support
for our findings. Another issue is that the information regarding
maternal influenza immunization was based on recall and could be
susceptible to information bias. However, the vaccination rates in
our study are similar to the rates computed by other authors for
Georgia, and to the United States national level coverage
estimated by the National Health Interview Survey [30,31].
The PRAMS dataset does not contain information regarding
the precise trimester of vaccination. Therefore, the effect of
vaccination in a specific trimester could not be evaluated.
Moreover, it is possible that mothers of premature infants had
less time to receive influenza vaccine than mothers of term infants
(i.e., reverse causality). On the other hand, since this was a
population-based study with a sampling strategy aimed at
producing representative estimates, the temporal distribution of
influenza vaccination in pregnancy would be similar to that of the
general population, hence adding to the generalizability of our
findings. The results of this study, nevertheless, need to be
replicated in other populations as it is plausible that the impact of
vaccines on birth outcomes would vary with the underlying
influenza epidemiology and demographic characteristics.
Supporting Information
Text S1 Impact of maternal influenza immunization on
likelihood of prematurity and SGA births.
Found at: doi:10.1371/journal.pmed.1000441.s001 (0.21 MB
DOC)
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Background. Maternal infections during pregnancy can
have harmful effects on both mother and baby. For example,
influenza is associated with increased morbidity and
mortality among pregnant women compared to women
who are not pregnant or who acquire influenza infection
after delivery. And some respiratory infections, especially
those that can cause maternal pneumonia such as influenza
virus, are known to be associated with the baby being
small—below the 10th percentile—for gestational age and
with an increased risk of preterm birth—birth before 37
weeks of gestation. Previous studies have shown that
inactivated influenza vaccination during pregnancy
provides protection against influenza virus for both mother
and baby. As there has been an increase in the rate of
preterm birth the United States from 9.5% in 1981 to 12.8%
in 2006, the impact of maternal influenza immunization on
birth outcomes has important public health implications and
is of particular interest during influenza pandemics.
Why Was This Study Done? Given that maternal
vaccination can protect babies from influenza virus, it is
plausible that influenza vaccination in pregnancy could
mitigate adverse birth outcomes such as prematurity and the
baby being small for gestational age. The researchers of this
study set out to evaluate this hypothesis by investigating
whether there was an association between women receiving
inactivated influenza vaccine during pregnancy and positive
birth outcomes for their babies in the population of the state
of Georgia, in the United States.
What Did the Researchers Do and Find? The researchers
conducted a retrospective cohort analysis of a large
surveillance dataset (the Georgia Pregnancy Risk
Assessment Monitoring System) to analyze the relationship
between receipt of inactivated influenza vaccine during any
trimester of pregnancy by mothers of infants born between
June 1, 2004, and September 30, 2006, and their baby being
premature or small for gestational age. The study period
encompassed the 2004–2005 and 2005–2006 influenza
seasons—the two most recent seasons for which the data
were available. The researchers did a stratified analysis for
the overall study period, and various periods during it, and
also weighted their analysis to adjust for possible
oversampling. They used logistic regression to evaluate the
association of maternal influenza vaccine and (a) prematurity
and (b) small for gestational age, and also used linear
regression to evaluate the statistical significance of
differences between vaccinated and unvaccinated women
for mean gestational age at first antenatal visit and mean
birth weight.
During the study period, 4,168 mother–baby pairs were
included in the analysis. Local influenza activity was detected
during 27 weeks (22.1%), and 578 women (14.9% [weighted])
had received the influenza vaccine during pregnancy, giving
a vaccination coverage of 19.2% (weighted) among mothers
of infants born during the assumed influenza season. In the
study sample, 1,547 babies (10.6% [weighted]) were born
premature, and 1,186 babies (11.2% [weighted]) were small
for gestational age. Infants who were born during the
assumed influenza season (October–May) and whose moth-
ers were vaccinated against influenza during pregnancy
were less likely to be premature than infants of unvaccinated
mothers born in the same period, with an adjusted odds
ratio of 0.60. The effect of maternal influenza vaccine on
reducing prematurity was the highest for infants born during
the period of widespread influenza activity, with 72% lower
odds of prematurity in infants of vaccinated mothers than
infants of unvaccinated mothers. Compared with newborns
of unvaccinated women, babies of vaccinated mothers also
had 69% lower odds of being small for gestational age
during the period of widespread influenza activity, but the
adjusted and unadjusted odd ratios were not significant for
the pre-influenza activity period.
What Do These Findings Mean? These results show that
there was an association between maternal immunization
with the inactivated influenza vaccine during pregnancy and
reduced likelihood of prematurity during local, regional, and
widespread influenza activity periods. In addition, during the
period of widespread influenza activity there was an
negative association between maternal receipt of influenza
vaccine and small for gestational age birth.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000441.
N More information about influenza vaccination during
pregnancy is available from the World Health Organization
and the UK National Health Service
N More information about the Georgia Pregnancy Risk
Assessment Monitoring System is also available
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